SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.
Key Highlights
- ➤Dennis Hruby retires as SIGA chief scientific officer after more than 30 years
- ➤Hruby will continue supporting SIGA as an advisor after retirement
- ➤TPOXX received U.S. FDA oral approval in 2018 and intravenous approval in 2022
- ➤TPOXX has been sold to more than 30 countries
Expert Statements
Diem Nguyen, Chief Executive Officer of SIGA Technologies
“Dennis Hruby's 30 years of service reflect a distinguished career defined by scientific rigor, vision, and an unwavering commitment to public health. As a foremost expert in infectious disease, he played an instrumental role in the development of TPOXX, a medical countermeasure that has fundamentally strengthened our nation's preparedness against smallpox”
Dennis Hruby, Former Executive Vice President and Chief Scientific Officer of SIGA Technologies
“I'm so proud of what we built at SIGA. When I joined, there was no antiviral treatment for smallpox. There is one now, and it is approved, stockpiled, and ready if ever needed to help save lives.”
Dennis Hruby, Former Executive Vice President and Chief Scientific Officer of SIGA Technologies
“I'm leaving the rest to a strong, successful team, and I look forward to seeing what comes next.”
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies (NASDAQ: SIGA), a commercial stage pharmaceutical company, announced today that Dennis Hruby, Ph.D., Executive Vice President and Chief Scientific Officer, will retire effective today, concluding more than 30 years with the Company.
Dr. Hruby joined SIGA in 1996 as a senior scientific advisor, became Vice President of Research in 1997, and has served as Chief Scientific Officer since 2000. Over that period, he led the development of tecovirimat, now marketed as TPOXX(®), from early-stage research through U.S. FDA approval of the oral formulation in 2018 and the intravenous formulation in 2022, as well as regulatory approvals in Canada, the European Union, the United Kingdom and Japan. TPOXX was the first antiviral therapeutic approved for the treatment of smallpox and has been sold to more than 30 countries.
Get started
Create a free account to read the full story.